Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 4;45(2):279–297. doi: 10.3892/ijmm.2019.4418

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Katoh et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

ADCs and CAR-Ts. ADCs or CAR-Ts targeting BCMA, CD19, CD22, CD30, CD79B, CLDN18, DLL3, EGFR, FGFR2, FGFR3, HER2 and other transmembrane or GPI-anchored proteins have been developed as investigational drugs. Anti-CD19 CAR-Ts (axicabtagene ciloleucel and tisagenlecleucel), an anti-CD22 ADC (inotuzumab ozogamicin), an anti-CD30 ADC (brentuximab vedotin), an anti-CD79B ADC (polatuzumab vedotin) and an anti-HER2 ADC (trastuzumab emtansine) have been approved by the US Food and Drug Administration for the treatment of patients with cancer. A DLL3-targeting ADC, rovalpituzumab tesirine (Rova-T), is in phase III clinical trials for the treatment of patients with small-cell lung cancer (registration nos. NCT03033511 and NCT03061812). CLDN18, Claudin 18.2; ADC, antibody-drug conjugate; CAR-Ts, chimeric antigen receptor-modified T cells; BCMA, tumor necrosis factor receptor superfamily member 17; DLL3, delta-like canonical Notch ligand 3; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor.